envafolimab
Showing 1 - 25 of 26
Immunotherapy;Envafolimab; Esophageal Cancer Trial (Envafolimab, Abraxane, Cisplatin)
Not yet recruiting
- Immunotherapy;Envafolimab; Esophageal Cancer
- Envafolimab
- +2 more
- (no location specified)
Apr 24, 2023
A Prospective, Randomized Controlled Study of Cyclophosphamide,
Not yet recruiting
- Epithelial Ovarian Cancer
- Envafolimab
-
Shijiazhuang, Hebei, ChinaHebei
Aug 20, 2023
Metastatic Colorectal Cancer Trial in Nanjing (Envafolimab, Trifluridine/Tipiracil, Bevacizumab)
Recruiting
- Metastatic Colorectal Cancer
- Envafolimab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Sep 24, 2023
Locally Advanced Cervical Cancer Trial in Chongqing (Envafolimab, Cisplatin, External Beam Radiotherapy (EBRT))
Not yet recruiting
- Locally Advanced Cervical Cancer
- Envafolimab
- +3 more
-
Chongqing, CHN, ChinaChongqing university Cancer Hospital
Apr 3, 2023
Neoadjuvant Envafolimab in Resectable and Locally Advanced
Not yet recruiting
- Locally Advanced Rectal Carcinoma
- MSI-High
- Envafolimab
- (no location specified)
Dec 9, 2022
Rectal Cancer Trial in Hangzhou (Envafolimab)
Recruiting
- Rectal Cancer
- Envafolimab
-
Hangzhou, Zhejiang, ChinaSir Run Run Shaw Hospital, Zhejiang University School of Medicin
May 4, 2023
Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma Trial (YH001, Envafolimab, Doxorubicin)
Recruiting
- Advanced Sarcoma
- +2 more
- YH001
- +2 more
-
Santa Monica, CaliforniaSarcoma Oncology Center
Dec 5, 2022
Colorectal Tumors Trial (Envafolimab, recombinant human endostatin (endostatin))
Not yet recruiting
- Colorectal Neoplasms
- Envafolimab
- recombinant human endostatin (endostatin)
- (no location specified)
Sep 19, 2022
Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma Trial (fruquintinib, Envafolimab)
Not yet recruiting
- Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
- fruquintinib
- Envafolimab
- (no location specified)
Jul 10, 2023
Esophageal Squamous Cell Carcinoma Trial (Envafolimab, Albumin-Bound Paclitaxel, Carboplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- Envafolimab
- +2 more
- (no location specified)
Sep 21, 2022
Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy Trial (Envafolimab)
Not yet recruiting
- Gastric/Gastroesophageal Junction Adenocarcinoma
- +2 more
- Envafolimab
- (no location specified)
May 18, 2022
Advanced Endometrial Cancer Trial in China (Envafolimab+Lenvatinib, Envafolimab)
Recruiting
- Advanced Endometrial Cancer
- Envafolimab+Lenvatinib
- Envafolimab
-
Beijing, Beijing, China
- +18 more
Jan 2, 2023
Metastatic or Recurrent Gastric Adenocarcinoma Trial in Nanjing (Envafolimab, Oxaliplatin, S1)
Recruiting
- Metastatic or Recurrent Gastric Adenocarcinoma
- Envafolimab
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Institute & Hospital
Apr 19, 2022
Ovarian Cancer, Epithelial Trial in Nanjing (Envafolimab, Lenvatinib, VP-16)
Not yet recruiting
- Ovarian Cancer, Epithelial
- Envafolimab
- +2 more
-
Nanjing, Jiangsu, ChinaZhongda Hospital
Jun 13, 2022
NSCLC Stage III Trial in Hefei (Envafolimab)
Not yet recruiting
- Non-small Cell Lung Cancer Stage III
- Envafolimab
-
Hefei, Anhui, ChinaAnhui Provincial Cancer Hospital
Jun 8, 2022
Colon Cancer Trial (Envafolimab)
Not yet recruiting
- Colon Cancer
- Envafolimab
- (no location specified)
Apr 13, 2022
Rectal Cancer Trial in Fuzhou (radiation, drug, procedure)
Not yet recruiting
- Rectal Cancer
- split-course hypofraction radiotherapy
- +3 more
-
Fuzhou, Fujian, ChinaPan Chi
Jul 23, 2023
Advanced Pancreatic Cancer Trial in Xuzhou (Envafolimab, Endostar, Nab paclitaxel)
Not yet recruiting
- Advanced Pancreatic Cancer
- Envafolimab
- +3 more
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Mar 18, 2022
Advanced Hepatocellular Carcinoma Trial in Hangzhou (Envafolimab, TACE, Lenvatinib)
Recruiting
- Advanced Hepatocellular Carcinoma
- Envafolimab
- +2 more
-
Hangzhou, Zhejiang, Chinathe First Affiliated Hospital, School of Medicine, Zhejiang Univ
Mar 13, 2022
NSCLC Trial in Changsha (envafolimab)
Enrolling by invitation
- Non-small Cell Lung Cancer
- envafolimab
-
Changsha, Hunan, Chinathe second Xiangya hospital
May 1, 2022
Colon Cancer, Neoadjuvant Therapy, Immunotherapy Trial in Guangzhou (Envafolimab, CAPEOX)
Recruiting
- Colon Cancer
- +2 more
- Envafolimab
- CAPEOX
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Aug 26, 2023
NSCLC Stage IV Trial in Xiamen (Envafolimab)
Active, not recruiting
- Non-small Cell Lung Cancer Stage IV
- Envafolimab
-
Xiamen, Fujian, ChinaFirst affiliated Hospital of Xiamen University
Sep 14, 2021
Non Small Cell Lung Cancer Trial in China (Chidamide, Envafolimab)
Recruiting
- Non Small Cell Lung Cancer
- Chidamide
- Envafolimab
-
Hefei, Anhui, China
- +11 more
Jan 17, 2022